<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075736</url>
  </required_header>
  <id_info>
    <org_study_id>35/13/03/02/08</org_study_id>
    <nct_id>NCT02075736</nct_id>
  </id_info>
  <brief_title>KTP Green Light Prostatectomy Compared With TUR-P in High Risk Patients</brief_title>
  <official_title>The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (120W) Compared With TUR-P When Treating Benign Prostatic Hyperplasia in High Risk Patients, A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <authority>Finland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare safety and efficacy of Green Light PVP
      (Photoselective Vaporization of the Prostate) compared to TUR-P in high risk patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Re-bleeding rate requiring hospitalization</measure>
    <time_frame>two months postoperatively</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>IPSS (International Prostate Symptom Score)</measure>
    <time_frame>0, 3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>symptom score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAN-PSS (Danish Prostate Symptom Score)</measure>
    <time_frame>0, 3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum flow rate (Qmax)</measure>
    <time_frame>0, 3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual urine</measure>
    <time_frame>0, 3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of catheterization</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected maximum of one week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected maximum of one week</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative bleeding</measure>
    <time_frame>Time of operation</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF (International Index of Erectile Function) questionnaire</measure>
    <time_frame>0,12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRUS (transrectal ultrasound)</measure>
    <time_frame>0, 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>BPH (Benign Prostatic Hyperplasia)</condition>
  <arm_group>
    <arm_group_label>KTP laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TUR-P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>device</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>KTP laser</intervention_name>
    <arm_group_label>KTP laser</arm_group_label>
    <other_name>Green laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TUR-P</intervention_name>
    <description>device</description>
    <arm_group_label>TUR-P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men with anticoagulant medication undergoing surgery for BPH

        Exclusion Criteria:

          -  Previous prostate surgery

          -  Carcinoma of the prostate

          -  Neurogenic bladder

          -  Bladder carcinoma
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannu T Koistinen, MD</last_name>
      <phone>+358504286139</phone>
      <email>hannu.koistinen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Hannu T Koistinen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 26, 2014</lastchanged_date>
  <firstreceived_date>February 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University</investigator_affiliation>
    <investigator_full_name>Hannu Koistinen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
